Get started
Author

Masafumi Kawanishi

Observed name: Kawanishi, Masafumi
Observed institution: Taisho Pharmaceutical (Japan)
ORCID: 0000-0003-4104-8548
Observed ORCID: 0000-0003-4104-8548
OpenAlex ID: A5004756806
Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
2022 · Tsutomu Takeuchi, Masafumi Kawanishi, et al. · Arthritis & Rheumatology · 63
Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)
2022 · Yoshiya Tanaka, Masafumi Kawanishi, et al. · Modern Rheumatology · 44
PDF
Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial)
2022 · Yoshiya Tanaka, Masafumi Kawanishi, et al. · Modern Rheumatology · 40
PDF
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
2023 · Tsutomu Takeuchi, Yukihiro Chino, et al. · Arthritis Research & Therapy · 38
PDF
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model
2007 · Norihisa Ishiwata, Kazuo Noguchi, et al. · Life Sciences · 17
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects
2009 · Miyuki Hori, Takehisa Iwama, et al. · European Journal of Pharmacology · 11
Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis
2024 · Yoshiya Tanaka, Yusuke Miyazaki, et al. · RMD Open · 10
PDF
Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis
2023 · Tsutomu Takeuchi, Megumi Nakanishi, et al. · Modern Rheumatology · 8
PDF
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis
2023 · Tsutomu Takeuchi, Yukihiro Chino, et al. · The Journal of Clinical Pharmacology · 5
PDF
Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 ‍mg Syringes for S.C. Injection), the first Nanobody® compound in Japan
2023 · Masafumi Kawanishi, Yasuyuki Fujii · Folia Pharmacologica Japonica · 4
PDF
Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis
2025 · Yoshiya Tanaka, Nobuko Horiuchi, et al. · Rheumatology and Therapy · 3
PDF
Impact of anti-drug antibodies and neutralising antibodies on safety and efficacy of ozoralizumab in rheumatoid arthritis
2026 · Masafumi Kawanishi, Tsutomu Takeuchi, et al. · Modern Rheumatology
Development of the Novel TNF Inhibitor NanozoraⓇ
2025 · Takayuki Sato, Tomofumi Kurokawa, et al. · Drug Delivery System
PDF
Upstream Region of the Ah Receptor Gene Necessary for Expression in Differentiation of HL60 Cells Into Macrophages
1998 · Masafumi Kawanishi, Yoshiaki Fujii‐Kuriyama, et al. · The Molecular Biology Society of Japan
Works count: 19
Citation count: 243
H-index: 8
I10-index: 7
Year
Topic
Type